Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Significance of Intravascular OCT-NIRAF
NCT06374498Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Open-label trial of pegulicianine in coronary artery disease (CAD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Plaque size estimation using OCT-NIRAF at 1 year, Plaque progression estimate using OCT-NIRAF at 1 year and 1 more. Started Jul 2024; status: enrolling by invitation.
02
Drugs
pegulicianine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06374498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374498.